Skip to content
Open access

Synthesis and in silico studies of hexahydroacridine derivatives as potential antitumor agents

Sep 2026 · Scientific Reports · Vol 16 · 0 citations · 99 references
Medicine

TL;DR

The anticancer potential of newly synthesized hexahydro-1,8-acridinedione derivatives featuring strategic structural modifications at positions 9 and 10 is evaluated, establishing compound 4d as a promising multi-target lead scaffold, warranting further optimization toward selective anticancer therapeutics.

Abstract

Despite advances in targeted cancer therapies, drug resistance and off-target toxicity remain major challenges, underscoring the need for new multi-targeted agents with improved selectivity. The present study evaluated the anticancer potential of newly synthesized hexahydro-1,8-acridinedione derivatives featuring strategic structural modifications at positions 9 and 10. The novelty of this work lies in the introduction of N-aryl substituents combined with C-9 biphenyl or 4-bromophenyl groups, a structural motif not previously reported for this chemotype. This dual modification was rationally designed to enhance π-π stacking interactions with kinase ATP-binding pockets while improving metabolic stability through fluorine substitution. Compounds were synthesized via a one-pot multicomponent reaction catalyzed by PTSA and characterized by IR, 1H/13C NMR, and LC–MS. Guided by structure-based design principles, five derivatives (4a, 4d, 4f., 5a, 5b) were evaluated for cytotoxicity against HSF, H460, A431, A549, and MDA-MB-231 cell lines. Compound 4d emerged as the most potent, with an IC₅₀ of 17.91 ± 2.8 µg/mL against H460 lung cancer cells and a high selectivity index (SI = 20.7), in addition to exhibiting a considerable anti-telomerase activity. Molecular docking revealed strong binding affinities of 4d with TOP2B (− 7.02 kcal/mol), p38 MAPK (− 7.05 kcal/mol), p53 (− 7.25 kcal/mol), and EGFR (− 6.55 kcal/mol), supported by MM-GBSA binding free energies (ΔGbind ≈ − 42 kcal/mol for 4d–EGFR). Furthermore, 100-ns Molecular Dynamics simulations confirmed the stability of the 4d-EGFR complex (RMSD ≈ 1.31 Å; persistent H-bonds with CYS773/GLN767). These findings establish compound 4d as a promising multi-target lead scaffold, warranting further optimization toward selective anticancer therapeutics.

Read PDF

Similar papers

Open access Aug 2026

Synthesis of New 1,4-dihydropyrimidine Derivatives, Breast Cancer Anticancer, and In-silico Studies

A sustainable and environmentally friendly approach for the synthesis of novel pyrimidine Schiff base derivatives through a multicomponent grinding reaction conducted at room temperature under solvent-free conditions is reported, suggesting that compound (3) may serve as a promising lead candidate for breast cancer the...

Alaa M. Abu Alnjaa · 0 citations
Aug 2026

Design, in silico study, synthesis and cytotoxic evaluation of new isatin-thiazole-sulfanilamide derivatives as potential carbonic anhydrase inhibitors

The synthesized compounds demonstrated significant inhibition of carbonic anhydrase IX activity through molecular docking and significant inhibition of cancer cell viability and the synthesized derivatives have a valuable cytotoxic activity against cancer cell.

Ammar Abdul Aziz Alibeg · 0 citations
Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · 0 citations
Aug 2026

Potential c-Met-targeted pyrazole-pyridine-oxadiazole hybrids: synthesis, anticancer activity, and computational rationale.

Findings identify 10d as a promising scaffold for further optimization and biological evaluation because it has the smallest HOMO-LUMO gap and highest chemical softness, consistent with its superior activity.

Prince A. Dave, Jay B. Maheta, Darshna K. Lakhnotra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.